Verdad Advisers’s Monopar Therapeutics MNPR Stock Holding History
Bought
Maintained
Sold
Other funds holding MNPR
SVCM
SL
Verdad Advisers's MNPR Position: Q3 2026 in Review
Verdad Advisers opened a new position in Monopar Therapeutics (MNPR) in Q3 2026: 8,409 shares worth $670K. The stake represents 0.72% of the portfolio and ranks #45 among its holdings.
106 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.
- Verdad Advisers held 8,409 shares of Monopar Therapeutics worth $670K as of Q3 2026.
- Monopar Therapeutics was a new Verdad Advisers position in Q3 2026.
- Monopar Therapeutics made up 0.72% of Verdad Advisers's portfolio in Q3 2026, its #45 holding.
- 106 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.
Based on Verdad Advisers's 13F filing for Q3 2026, filed 16 Nov 2026.